Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question
Executive Summary
Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.
You may also be interested in...
Genentech Likely To Wait For Survival Data For U.S. Filing Of Avastin In Ovarian Cancer
Avastin proves progression-free survival benefit for tough-to-treat patients in AURELIA, the drug’s fourth positive Phase III ovarian cancer study. Genentech says it plans to “engage” with FDA regarding a filing, but acknowledges that the agency may want more data, possibly showing an overall survival benefit.
Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO
Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.
Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO
Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.